Table 2.

Pathogen reduction technology systems and products currently approved and in use

System/product	Manufacturer	Mechanism	Product(s) for which use is approved	Used in⁎
INTERCEPT Blood System [131] (technology)	Cerus	Photosensitizer (amotosalen) + UV A (320-400 nm) illumination	Plasma: •Apheresis or whole blood-derived	Plasma: 13 countries
			Platelets: •Apheresis or whole blood-derived •In plasma or approved additive solutions (InterSol and SPP +)	Platelets: 22 countries
Mirasol Pathogen Reduction System [132] (technology)	TerumoBCT	Photosensitizer (riboflavin) + UV B (280-360 nm) illumination	Plasma: •Apheresis or whole blood-derived	Plasma: 11 countries
			Platelets: •Apheresis or whole blood-derived •In plasma or platelet additive solution	Platelets: 18 countries
The THERAFLEX MB-Plasma System§[133], [134] (technology)	Macopharma	Filtration (0.65 μm), methylene blue + visible light (~ 400-700 nm) illumination	Single unit fresh frozen plasma •Apheresis or whole blood-derived	15 countries
Octaplas [135] (product)	Octapharma	Solvent/detergent treatment (1% trinitrobutyl phosphate/1% Triton X-100)	Pooled plasma •Apheresis or whole blood-derived	32 countries

^⁎Sourced from [94].

^§The THERAFLEX UV-platelets system, which uses shortwave UVC light (254 nm) without the addition of a photoactive agent, is under further clinical evaluation and is not in routine use [136].